Compare UFPT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | IOVA |
|---|---|---|
| Founded | 1963 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 1996 | 2008 |
| Metric | UFPT | IOVA |
|---|---|---|
| Price | $192.02 | $3.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $289.00 | $9.11 |
| AVG Volume (30 Days) | 155.3K | ★ 14.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.44 | 14.84 |
| EPS | ★ 8.75 | N/A |
| Revenue | ★ $602,797,000.00 | N/A |
| Revenue This Year | $8.12 | $51.55 |
| Revenue Next Year | $5.72 | $37.55 |
| P/E Ratio | $21.93 | ★ N/A |
| Revenue Growth | ★ 19.50 | N/A |
| 52 Week Low | $178.26 | $1.64 |
| 52 Week High | $274.93 | $5.63 |
| Indicator | UFPT | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 44.16 |
| Support Level | $185.63 | $2.02 |
| Resistance Level | $206.13 | $4.34 |
| Average True Range (ATR) | 7.90 | 0.25 |
| MACD | 1.31 | -0.11 |
| Stochastic Oscillator | 28.56 | 19.21 |
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.